Ocular Immunology and Inflammation最新文献

{"title":"Comparative Risk of Uveitis with Bisphosphonate Use in Osteoporosis: A Population-Based Cohort Study Using the TriNetX US Database.","authors":"Hui-Min Hsieh, Yu-Ting Zheng, Wei-Shan Chang, Shwu-Jiuan Sheu","doi":"10.1080/09273948.2026.2734569","DOIUrl":"https://doi.org/10.1080/09273948.2026.2734569","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate associations between bisphosphonates and uveitis in patients with osteoporosis.</p><p><strong>Methods: </strong>This population-based retrospective cohort study used de-identified data from the TriNetX US Collaborative Network. Patients with at least two osteoporosis diagnoses between 2013 and 2024 were classified as bisphosphonate users or nonusers. Bisphosphonate users were further stratified according to the presence or absence of autoimmune diseases before treatment initiation. Propensity score matching at a 1:1 ratio was performed to balance baseline characteristics and reduce selection bias. Cox proportional hazards models were used to estimate the risks of overall and subtype-specific uveitis, and Kaplan-Meier analyses were conducted to compare cumulative incidence after matching.</p><p><strong>Results: </strong>Bisphosphonate use was associated with increased risks of overall and anterior uveitis, particularly within the first month of treatment (overall uveitis: hazard ratio [HR], 2.22; 95% CI, 1.50-3.26; anterior uveitis: HR, 2.57; 95% CI, 1.66-3.98). Although the effect estimates decreased over time, the associations remained significant throughout follow-up. Subgroup analyses showed that patients with autoimmune diseases had higher risks of overall uveitis throughout follow-up (HR, 2.26; 95% CI, 2.02-2.54), anterior uveitis (HR, 2.24; 95% CI, 1.98-2.53), and posteriors uveitis (HR, 2.54; 95% CI, 1.91-3.38).</p><p><strong>Conclusion: </strong>Bisphosphonate use is associated with an increased risk of uveitis among osteoporosis patients, especially in those with pre-existing autoimmune diseases. Given the widespread use of bisphosphonates in osteoporosis treatment, increased clinician awareness may facilitate early recognition and management of uveitis risk in this population.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-8"},"PeriodicalIF":1.7,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149002202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When OCT Speaks Before the Fundus Does: Early ASHH Sign Revealing Acute Outer Retinopathy.","authors":"Marta Corcuera Munguía, Roberto Gallego Pinazo, María Capote Diez, Felix Armadá Maresca","doi":"10.1080/09273948.2026.2734568","DOIUrl":"https://doi.org/10.1080/09273948.2026.2734568","url":null,"abstract":"<p><strong>Purpose: </strong>Within the acute zonal occult outer retinopathy (AZOOR) complex, acute outer retinopathy (AOR) has recently been proposed as an entity with rapid progression which remains under study. The present report aims to illustrate the clinical presentation, multimodal imaging findings, and disease course of AOR and to emphasize its role within the AZOOR spectrum.</p><p><strong>Methods: </strong>We report a 19-year-old female presenting with acute photopsia and nasal scotoma in her left eye with a subtle whitish area in the fundus examination and the ASHH on OCT. Her visual acuity declined from 20/30 to 20/200 and to hand movements (HM), despite initiation of systemic corticosteroids. Partial structural recovery occurred over the following months without functional improvement.</p><p><strong>Results: </strong>This case highlights the potentially aggressive course of AOR and supports the role of the ASHH sign as an early marker of complete photoreceptor disruption. The rapid progression and the dissociation between structural recovery and persistent visual loss suggest that the underlying pathophysiological mechanisms remain incompletely understood.</p><p><strong>Conclusion: </strong>AOR should be suspected in patients with typical AZOOR symptoms and the ASHH sign on OCT despite minimal fundus findings. Multimodal imaging, particularly OCT, is essential for early diagnosis and monitoring of disease progression.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-4"},"PeriodicalIF":1.7,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149002231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAK Inhibitors for Refractory Non-Infectious Ocular Inflammation: A Systematic Review and Meta-Analysis of Efficacy, Safety, and Optimal Positioning.","authors":"I Merve Uçar Baytaroğlu, Ata Baytaroğlu, Şerife Nur Çiftci, Meryem Ümit Kurban, Suzan Doğruya, Gülay Alp","doi":"10.1080/09273948.2026.2735413","DOIUrl":"https://doi.org/10.1080/09273948.2026.2735413","url":null,"abstract":"<p><strong>Purpose: </strong>Janus kinase (JAK) inhibitors have entered clinical testing for non-infectious ocular inflammation, but trial evidence is unsynthesized. We evaluated efficacy and safety within a pre-specified tiered framework.</p><p><strong>Methods: </strong>We searched five databases, three registries, and grey literature to July 4, 2026. Eligible studies were pre-assigned to Stratum A (systemic agents for intraocular or scleral inflammation; primary) or Stratum B (topical, ocular surface disease); bias was assessed with RoB 2 and ROBINS-I. Single-arm proportions were pooled with a beta-binomial model; with I² above the pre-specified 75%, Synthesis Without Meta-analysis (SWiM) was primary.</p><p><strong>Results: </strong>Seven studies (four randomized by design; 465 participants) were included: 138 in Stratum A (systemic), 327 in the single Stratum B trial. In Stratum A, disease control ranged from 33.3% to 100%; five of six showed a favorable direction. The pooled estimate, 76.2% (95% CI 55.8-96.5), fell to 57.6% at 24 weeks or excluding two 100%-response studies; a prediction interval (1.0-87.1; I² = 91.5%) confirmed no single value is reliable. In HUMBOLDT, the only placebo-controlled trial of a systemic agent, filgotinib reduced treatment failure (RR 0.55, 95% CI 0.34-0.92; NNT 3.3; <i>p</i> = 0.006). Serious adverse events occurred in 5/140 systemically exposed patients (3.6%, 95% CI 1.2-8.1), with no thromboembolic, major cardiovascular, or malignant events.</p><p><strong>Conclusion: </strong>Systemic JAK inhibitors show a consistent favorable direction in refractory intraocular inflammation, most reliably filgotinib, but heterogeneity and very low certainty preclude pooling. They may serve as third- or fourth-line agents pending Phase 3 data.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-15"},"PeriodicalIF":1.7,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148990439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Younger Age-Related Incidence of Corneal Limbitis Following Pterygium Excision Combined with Conjunctival-Limbal Autograft.","authors":"Dong Hee Ha, Young In Yun, Seung Hyeun Lee, Ja Young Oh, Kyoung Woo Kim","doi":"10.1080/09273948.2026.2730463","DOIUrl":"https://doi.org/10.1080/09273948.2026.2730463","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the incidence, clinical characteristics, and risk factors of corneal limbitis following pterygium excision with conjunctival-limbal autograft.</p><p><strong>Methods: </strong>This retrospective study included 63 eyes of 61 patients with primary nasal pterygium who underwent pterygium excision with conjunctival-limbal autograft. Patients were assessed perioperatively using anterior segment swept-source optical coherence tomography (AS SS-OCT; Anterion, Heidelberg, Germany), and postoperative complications were evaluated during follow-up. Risk factors for corneal limbitis, including age and preoperative AS SS-OCT-guided morphological and optical parameters, were analyzed.</p><p><strong>Results: </strong>Corneal limbitis occurred in 12 of 63 eyes (19.0%), with a mean onset of 19.1 ± 10.9 weeks postoperatively. Eyes with limbitis were significantly younger than those without (45.3 ± 8.1 vs. 60.5 ± 9.5 years, <i>p</i> < 0.001), while other demographic, clinical severity, and morphological parameters were not significantly different between the two groups. On multivariate logistic regression analysis, younger age was the only independent risk factor for postoperative corneal limbitis (<i>p</i> = 0.007, OR = 0.674). ROC curve analysis identified a cutoff age of 49.5 years (AUC = 0.895, sensitivity 92.2%, specificity 83.3%). The incidence of corneal limbitis was significantly higher in patients younger than 50 years (10/14 eyes, 71.4%) than in those aged 50 years or older (2/49 eyes, 4.1%) (<i>p</i> < 0.001). All limbitis cases resolved with anti-inflammatory treatment.</p><p><strong>Conclusions: </strong>Corneal limbitis may represent a notable postoperative complication following pterygium excision with conjunctival-limbal autograft, occurring predominantly in younger patients. Younger age appeared to be associated with a higher risk, although this finding requires validation in larger cohorts.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-9"},"PeriodicalIF":1.7,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148990554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Safety and Effectiveness of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis: A Post-Marketing Surveillance Study in Korea.","authors":"Seung Woo Choi, Eun Jeen Ryu, Se Joon Woo","doi":"10.1080/09273948.2026.2725801","DOIUrl":"10.1080/09273948.2026.2725801","url":null,"abstract":"<p><strong>Purpose: </strong>This post-marketing surveillance study reports the real-world safety and effectiveness of adalimumab (Humira®, AbbVie Inc.) among patients with non-infectious intermediate, posterior, or panuveitis (NIIPPU) in Korea.</p><p><strong>Methods: </strong>The study was conducted at 17 medical centres from January 2018 to July 2020. Safety (155 patients) was analysed by collecting adverse events (AEs) and adverse drug reactions (ADRs) data. Effectiveness assessments (148 patients) included anterior chamber cell grade, vitreous haze grade, and best corrected visual acuity (BCVA) change.</p><p><strong>Results: </strong>At baseline, the mean duration of uveitis was 3.9 ± 4.0 years (<i>n</i> = 101) and the mean number of relapses in the past year was 2.5 (<i>n</i> = 52). The most common anatomical uveitis phenotype was panuveitis (<i>n</i> = 110, 71.0%). One patient received prior infliximab; within the previous 3 months, 75.4% and 93.3% of patients received glucocorticoids and immunosuppressants, respectively. The mean daily corticosteroid dose decreased from 9.7 ± 7.8 mg at the start of the study to 6.6 ± 6.0 mg at the end of the study (<i>p</i> < 0.0001). AEs and ADRs were reported in 13 patients (8.4%, 1.9% serious) and 5 patients (3.2%), respectively. The most common ADR was injection-site discomfort. Twenty-nine patients (18.7%) discontinued adalimumab within 6 months; 34 patients discontinued during follow-up, most commonly for cost issues (64.7%). Three patients discontinued adalimumab due to AEs. Regarding effectiveness, from baseline to 22 weeks, anterior chamber inflammation and vitreous haze tended to improve significantly; there was no BCVA worsening.</p><p><strong>Conclusion: </strong>In the real-world setting, adalimumab treatment showed an acceptable safety profile, with serious AEs reported in three patients but no serious ADRs related to adalimumab, and demonstrated potential effectiveness in Korean patients with NIIPPU.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-10"},"PeriodicalIF":1.7,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148990498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metagenomic Deep Sequencing Identifies Gene Mutations Associated with Chemotherapeutic Resistance in Vitreoretinal Lymphoma.","authors":"Thananop L Pothikamjorn, Thuy A Doan, Armin Hinterwirth, Jay M Stewart, John A Gonzales","doi":"10.1080/09273948.2026.2677102","DOIUrl":"https://doi.org/10.1080/09273948.2026.2677102","url":null,"abstract":"<p><strong>Purpose: </strong>To identify gene mutations associated with chemotherapeutic resistance in patients with vitreoretinal lymphoma (VRL) using metagenomic deep sequencing (MDS) of intraocular specimens.</p><p><strong>Methods: </strong>Patients with VRL confirmed by cytopathology and immunohistochemistry, flow cytometry, and/or polymerase chain reaction for MYD88, were included. Intraocular specimens underwent MDS of the host genome. Gene mutations were identified and cross-referenced with the Catalogue of Somatic Mutations in Cancer database to determine associations with chemotherapeutic resistance.</p><p><strong>Results: </strong>Forty-nine patients with VRL underwent MDS, with six specimens from four patients revealing eight gene mutations associated with chemotherapeutic resistance. Four specimens from three patients harbored mutations associated with methotrexate resistance, the mainstay of VRL treatment. In one patient, serial sampling from the initial vitrectomy and two subsequent recurrences revealed distinct resistance-associated mutations at each time point. Despite multi-agent therapy including rituximab, consolidation regimens, and lenalidomide, this patient ultimately succumbed to the disease, whereas the other three patients remained in long-term remission.</p><p><strong>Conclusions: </strong>Our findings demonstrated that specific gene mutations associated with chemotherapeutic resistance may be harbored by VRL. The detection of different resistance mutations at sequential time points in one patient may reflect clonal selection, treatment pressure, or variable detection sensitivity. The ability to easily sample ocular fluid and detect different mutations associated with tumor recurrence or persistence may provide insights into tumor pathogenesis and could inform prognosis and influence treatment decisions. These findings establish a foundation for developing targeted PCR assays for identified resistance genes, which could transform clinical practice in VRL.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-7"},"PeriodicalIF":1.7,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148990414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structural and Optical Corneal Alterations in Inactive Herpetic Keratitis: A Quantitative Tomographic Analysis.","authors":"Irem Onal, Gulcicek Cayhan, Fahri Onur Aydin, Yusuf Berk Akbas, Ali Ceylan, Burcin Kepez Yildiz","doi":"10.1080/09273948.2026.2735428","DOIUrl":"https://doi.org/10.1080/09273948.2026.2735428","url":null,"abstract":"<p><strong>Purpose: </strong>To quantitatively characterize the structural and optical changes in the cornea in inactive herpetic keratitis and, secondarily, to evaluate whether these parameters vary according to lesion location and depth of vascularization.</p><p><strong>Methods: </strong>This prospective cross-sectional study included 37 patients with unilateral inactive stromal and epithelial herpetic keratitis. Affected eyes were compared with contralateral healthy eyes. Corneal tomography was used to assess corneal thickness, epithelial and stromal profiles, anterior and posterior elevation, and higher-order aberrations (HOAs). Lesions were classified by location and vascularization depth.</p><p><strong>Results: </strong>Affected eyes showed significantly worse visual acuity, increased astigmatism, and greater corneal irregularity (all <i>p</i> < 0.001). Stromal thinning, epithelial thickening, increased anterior elevation, and altered posterior elevation were observed at lesion sites (<i>p</i> = 0.044, <i>p</i> < 0.001, <i>p</i> < 0.001, <i>p</i> = 0.015; respectively). Total HOAs and higher-order RMS components were significantly elevated (<i>p</i> < 0.001), while vertical coma and spherical aberration coefficients differed significantly between affected and fellow eyes (<i>p</i> = 0.024 and <i>p</i> = 0.008, respectively). No significant differences in structural or optical parameters were observed among vascularization depth subgroups. Spherical aberration differed significantly among lesion-location subgroups (<i>p</i> = 0.039), with a significant difference between the central and paracentral groups after Bonferroni correction (adjusted <i>p</i> = 0.034).</p><p><strong>Conclusion: </strong>Inactive herpetic keratitis is associated with structural and optical alterations beyond stromal opacity. Tomographic and wavefront analysis may improve understanding of visual impairment and support individualized management.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-10"},"PeriodicalIF":1.7,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148990559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality and Cancer Response in Patients with Immune Check Point Inhibitor Associated Uveitis.","authors":"Ryan Duong, Matthew Oley, Joseph Wright, Abdullah Abou-Samra, Elizabeth Gaughan, Arthi Venkat","doi":"10.1080/09273948.2026.2734581","DOIUrl":"https://doi.org/10.1080/09273948.2026.2734581","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate mortality and cancer response in oncology patients who developed secondary uveitis during treatment with immune checkpoint inhibitors (ICI).</p><p><strong>Methods: </strong>Single-center retrospective case series of patients with all-cause metastatic cancer who developed secondary treatment-related uveitis between 2016 and 2024 versus age- and cancer-matched control.</p><p><strong>Results: </strong>Of 3000 screened oncology patients being treated with ICI therapy for metastatic disease, 28 patients who developed secondary uveitis were identified. The median time from ICI initiation and uveitis diagnosis was 124 days. Quiescence was achieved in 86% of cases at mean time 117 ± 112 days after diagnosis. Immunotherapy was paused during the course of uveitis treatment in a total of 22 (79%) cases, of which the cessation was attributable to uveitis alone in 17 (77%) cases. ICI treatment was resumed in 11 of these cases following control of uveitis. Visual acuity was improved or stable in 60% eyes with only 2 patients having worse than 20/400 in one eye. Compared to age‑matched controls, patients who developed secondary uveitis achieved greater rate of positive or desired cancer response (75% vs 50%, <i>p</i> = 0.03). Mortality rate in the uveitis group was lower (29%) compared to age‑matched controls (46%) (<i>p</i> = 0.17). Mean survival time from date of diagnosis was 160 ± 19 in the uveitis group compared to 124 ± 20 months in the non-uveitis group (<i>p</i> = 0.35).</p><p><strong>Conclusions: </strong>More favorable outcomes were observed in patients who developed secondary uveitis from immune checkpoint therapy.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-5"},"PeriodicalIF":1.7,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148977446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Herpes Viral Co-Infection in Benign Mooren's Ulcer.","authors":"Yang Kyung Cho, Dae Won Kim","doi":"10.1080/09273948.2026.2734627","DOIUrl":"https://doi.org/10.1080/09273948.2026.2734627","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the incidence, clinical characteristics, and possible herpes viral etiology of Mooren's ulcer.</p><p><strong>Methods: </strong>A retrospective chart review of 29 eyes in 29 patients diagnosed with Mooren's ulcer was performed to evaluate the incidence of co-infection with herpes epithelial keratitis during the episode of Mooren's ulcer.</p><p><strong>Results: </strong>Eleven of the 29 eyes showed a delayed response to the initial immunosuppressive treatment. Using polymerase chain reaction analysis of collected tear samples and corneal epithelial debris, 5 of those 11 eyes were diagnosed with simultaneous <i>Herpes simplex</i> keratitis (HSK) infection at both the first and recurrent episodes. At recurrence, simultaneous immunosuppressive and antiviral treatment accelerated patient recovery, compared with the sequential treatment (antivirals after initial immunosuppressives) of the 1^st episode (<i>p</i> < 0.01).</p><p><strong>Conclusions: </strong>Idiopathic Mooren's ulcer can be related to peripheral HSK co-infection. During co-infection, simultaneous antiviral and immunosuppressive treatment should be considered to prevent aggravating the peripheral HSK while treating the underlying Mooren's ulcer.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-8"},"PeriodicalIF":1.7,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148977460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anterior Chamber Angle Alterations in Bilateral Acute Iris Transillumination Syndrome.","authors":"Furkan Ozer, Onur Ocaktan, Duygu Gülmez Sevim","doi":"10.1080/09273948.2026.2734574","DOIUrl":"https://doi.org/10.1080/09273948.2026.2734574","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate anterior chamber angle characteristics in patients with bilateral acute iris transillumination (BAIT) using swept-source anterior segment optical coherence tomography (AS-OCT) and to investigate the diagnostic performance of angle parameters for distinguishing BAIT from healthy controls.</p><p><strong>Methods: </strong>This cross-sectional study included 15 patients diagnosed with BAIT and 15 healthy controls with a comparable age and sex distribution. All participants underwent comprehensive ophthalmic examination and anterior segment imaging using the ANTERION swept-source AS-OCT system. Measurements included angle opening distance (AOD), trabecular-iris space area (TISA), scleral spur angle (SSA), aqueous depth (AQD), lens thickness, lens vault, and other anterior segment biometric parameters. Group comparisons were performed. Correlation analyses were conducted to evaluate associations between angle parameters and ocular biometric measurements. Receiver operating characteristic (ROC) analysis was performed to assess the diagnostic utility of significant angle parameters.</p><p><strong>Results: </strong>Patients with BAIT demonstrated significantly lower AOD and TISA values compared with healthy controls, whereas SSA measurements were comparable between groups. Correlation analysis revealed significant positive associations of AOD, TISA, and SSA measurements with AQD and significant negative associations with lens thickness. ROC analysis demonstrated good discriminatory ability for both AOD750 MIN and TISA750 MIN in distinguishing BAIT eyes from controls. Mean intraocular pressure decreased from 24.4 ± 16.2 mmHg at presentation to 14.7 ± 2.1 mmHg at 12 months, although the difference was not statistically significant (<i>p</i> = 0.226).</p><p><strong>Conclusions: </strong>BAIT may be associated with measurable alterations in anterior chamber angle configuration characterized predominantly by reduced AOD and TISA values.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-10"},"PeriodicalIF":1.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}